Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Preferred Stock Liabilities (2022 - 2023)

Historic Preferred Stock Liabilities for TriSalus Life Sciences (TLSI) over the last 2 years, with Q2 2023 value amounting to $12.0 million.

  • TriSalus Life Sciences' Preferred Stock Liabilities fell 9518.27% to $12.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $12.0 million, marking a year-over-year decrease of 9518.27%. This contributed to the annual value of $164.0 million for FY2022, which is N/A changed from last year.
  • TriSalus Life Sciences' Preferred Stock Liabilities amounted to $12.0 million in Q2 2023, which was down 9518.27% from $20.2 million recorded in Q1 2023.
  • TriSalus Life Sciences' 5-year Preferred Stock Liabilities high stood at $250.8 million for Q3 2022, and its period low was $12.0 million during Q2 2023.